[{"address1": "20 Commerce Drive", "address2": "Suite 135", "city": "Cranford", "state": "NJ", "zip": "07016", "country": "United States", "phone": "732 980 4500", "website": "https://enzon.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Enzon Pharmaceuticals, Inc., together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs. The company was formerly known as Enzon, Inc and changed its name to Enzon Pharmaceuticals, Inc. in December 2002. Enzon Pharmaceuticals, Inc. was incorporated in 1981 and is headquartered in Cranford, New Jersey.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Richard L. Feinstein CPA", "age": 81, "title": "CEO, CFO & Secretary", "yearBorn": 1943, "fiscalYear": 2023, "totalPay": 224068, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "open": 0.17, "dayLow": 0.1592, "dayHigh": 0.17, "regularMarketOpen": 0.17, "regularMarketDayLow": 0.1592, "regularMarketDayHigh": 0.17, "exDividendDate": 1569801600, "trailingPE": "Infinity", "volume": 9530, "regularMarketVolume": 9530, "averageVolume": 83147, "averageVolume10days": 57140, "averageDailyVolume10Day": 57140, "bid": 0.15, "ask": 0.1688, "marketCap": 12616482, "fiftyTwoWeekLow": 0.06, "fiftyTwoWeekHigh": 0.24, "priceToSalesTrailing12Months": 485.2493, "fiftyDayAverage": 0.1362, "twoHundredDayAverage": 0.1304, "trailingAnnualDividendYield": "NaN", "currency": "USD", "enterpriseValue": 9970425, "profitMargins": 58.538464, "floatShares": 30114059, "sharesOutstanding": 74214600, "sharesShort": 259381, "sharesShortPriorMonth": 298381, "sharesShortPreviousMonthDate": 1460678400, "dateShortInterest": 1463097600, "sharesPercentSharesOut": 0.0058999998, "heldPercentInsiders": 0.108389996, "heldPercentInstitutions": 0.48584, "shortRatio": 1.71, "shortPercentOfFloat": 0.0068, "impliedSharesOutstanding": 74214600, "bookValue": 0.037, "priceToBook": 4.5945945, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "earningsQuarterlyGrowth": -0.209, "netIncomeToCommon": 247000, "enterpriseToRevenue": 383.478, "52WeekChange": 1.125, "SandP52WeekChange": 0.21142256, "lastDividendValue": 0.12, "lastDividendDate": 1569801600, "exchange": "OQX", "quoteType": "EQUITY", "symbol": "ENZN", "underlyingSymbol": "ENZN", "shortName": "Enzon Pharmaceuticals, Inc.", "longName": "Enzon Pharmaceuticals, Inc.", "firstTradeDateEpochUtc": 445703400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "0587b8b7-aa7f-39dd-a561-8adfc18ffdbb", "messageBoardId": "finmb_269599", "gmtOffSetMilliseconds": -18000000, "currentPrice": 0.17, "recommendationKey": "none", "totalCash": 46633000, "totalCashPerShare": 0.628, "quickRatio": 106.468, "currentRatio": 107.237, "totalRevenue": 26000, "returnOnAssets": -0.01615, "returnOnEquity": 0.03258, "grossProfits": 26000, "freeCashflow": -737250, "operatingCashflow": 1351000, "grossMargins": 1.0, "operatingMargins": -46.846153, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-02-08"}]